Cocrystal Pharma, Inc. SEC filings COCP
Cocrystal Pharma, Inc. has 672 filings in SEC EDGAR's recent list, going back to Sep 20, 2007. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 9, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 27, 2026 | — |
| DEF 14A | Proxy statement | May 27, 2026 | May 27, 2026 |
| DEFA14A | Additional proxy material | May 5, 2025 | — |
| DEF 14A | Proxy statement | May 5, 2025 | May 5, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEF 14A | Proxy statement | May 7, 2024 | May 7, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 26, 2024 | Apr 26, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Apr 28, 2023 |
| DEF 14A | Proxy statement | Apr 11, 2022 | Apr 11, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2022 | Apr 1, 2022 |
| DEFA14A | Additional proxy material | Jun 7, 2021 | — |
| DEFA14A | Additional proxy material | Jun 1, 2021 | — |
| DEFA14A | Additional proxy material | May 28, 2021 | — |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEF 14A | Proxy statement | Apr 26, 2021 | Apr 26, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2021 | Apr 16, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Apr 28, 2020 |
| DEF 14A | Proxy statement | Apr 30, 2019 | Apr 30, 2019 |
| DEFA14A | Additional proxy material | Jun 25, 2018 | — |
| DEF 14A | Proxy statement | Jun 25, 2018 | Jun 25, 2018 |
| PRE 14A | Preliminary proxy statement | Jun 13, 2018 | Jun 13, 2018 |
| DEF 14C | Information statement | Oct 17, 2017 | Oct 16, 2017 |
| PRE 14C | Filing | Oct 4, 2017 | Oct 4, 2017 |
| DEFA14A | Additional proxy material | Jul 22, 2016 | — |
| DEF 14A | Proxy statement | Jun 17, 2016 | Jul 28, 2016 |
| PRE 14A | Preliminary proxy statement | Jun 14, 2016 | Jul 28, 2016 |
| DEF 14A | Proxy statement | Jun 1, 2015 | Jun 29, 2015 |
| PRE 14A | Preliminary proxy statement | May 20, 2015 | May 18, 2015 |
| DEF 14A | Proxy statement | Jan 7, 2015 | Mar 3, 2015 |
| PRE 14A | Preliminary proxy statement | Dec 24, 2014 | Dec 23, 2014 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COCP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1412486
- Former names
- BIOZONE PHARMACEUTICALS, INC. (until Mar 25, 2014); International Surf Resorts, Inc. (until Mar 4, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.